T2DM CKD stage 3-4 patients T2DM CKD stage 3-4 patients
Conditions
Interventions
oral 15mg per day pioglitazone,standard treatment
Experimental Drug,No Intervention No treatment
Pioglitazone group,Control group
Sponsors
None
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. age of 18 years or more 2. T2DM with stable HbA1c 6-8% 3. eGFR 15-59 ml/min/1.73m2 with stable renal function in 12 weeks 4. Stable calcium and phosphate level
Exclusion criteria
Exclusion criteria: 1. history of AKI in 12 weeks 2. History of heart failure or volume overload within 12 weeks 3. History of frequent hypoglycemia 4. History of fracture or bladder cancer 5. Previous pioglitazone and insulin use 6. Previous side effects of pioglitazone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| reduction of serum intact FGF-23 at 16 weeks after end of intervention laboratory test | — |
Secondary
| Measure | Time frame |
|---|---|
| changes of serum calcium, phosphate, intact PTH, HbA1c and HOMA-IR 16 weeks laboratory test | — |
Countries
Thailand
Contacts
Public ContactWutipong Triwatana
Department of internal medicine, Phramongkutklao hospital
Outcome results
None listed